Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis.
Smith E, Huang J, Viswabandya A, Maze D, Malik S, Cheung V, Siddiq N, Claudio J, Arruda A, Kennedy J, Bankar A, Law AD, Lam W, Michelis FV, Kim D, Lipton J, Kumar R, Mattsson J, McNamara C, Sibai H, Xu W, Gupta V. Smith E, et al. Among authors: mcnamara c. Transplant Cell Ther. 2021 Jul;27(7):600.e1-600.e8. doi: 10.1016/j.jtct.2021.03.027. Epub 2021 Mar 30. Transplant Cell Ther. 2021. PMID: 33798769 Free article.
Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study.
Bartoszko J, Panzarella T, McNamara CJ, Lau A, Schimmer AD, Schuh AC, Sibai H, Maze D, Yee KWL, Devlin R, Gupta V. Bartoszko J, et al. Among authors: mcnamara cj. Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):774-781. doi: 10.1016/j.clml.2017.06.031. Epub 2017 Jun 29. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28711573
Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
Sibai H, Chen R, Liu X, Falcone U, Schimmer A, Schuh A, Law A, McNamara C, Maze D, Yee K, Minden M, Chan SM, Gupta V, Murphy T, Sakurai N, Atenafu EG, Brandwein JM, Seki JT. Sibai H, et al. Among authors: mcnamara c. Br J Haematol. 2020 Dec;191(5):748-754. doi: 10.1111/bjh.16695. Epub 2020 May 12. Br J Haematol. 2020. PMID: 32395867 Free article. Clinical Trial.
Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Daher-Reyes G, Kim T, Novitzky-Basso I, Kim KH, Smith A, Stockley T, Capochichi JM, Al-Shaibani Z, Pasic I, Law A, Lam W, Michelis FV, Gerbitz A, Viswabandya A, Lipton J, Kumar R, Mattsson J, Schimmer A, McNamara C, Murphy T, Maze D, Gupta V, Sibai H, Chan S, Yee K, Minden M, Zhang Z, Schuh A, Kim DDH. Daher-Reyes G, et al. Among authors: mcnamara c. Bone Marrow Transplant. 2021 Aug;56(8):1908-1918. doi: 10.1038/s41409-021-01255-4. Epub 2021 Mar 25. Bone Marrow Transplant. 2021. PMID: 33767401
Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study.
Bankar A, Alibhai S, Smith E, Yang D, Malik S, Cheung V, Siddiq N, Claudio J, Arruda A, Tsui H, Capo-Chichi JM, Kennedy JA, McNamara C, Sibai H, Maze D, Xu W, Gupta V. Bankar A, et al. Among authors: mcnamara c. Br J Haematol. 2021 Aug;194(3):557-567. doi: 10.1111/bjh.17617. Epub 2021 Jun 15. Br J Haematol. 2021. PMID: 34131896 Free PMC article. Clinical Trial.
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK. Tamari R, et al. Among authors: mcnamara c. Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151. doi: 10.1016/j.bbmt.2019.01.002. Epub 2019 Jan 6. Biol Blood Marrow Transplant. 2019. PMID: 30625392 Free PMC article.
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Puckrin R, Atenafu EG, Claudio JO, Chan S, Gupta V, Maze D, McNamara C, Murphy T, Shuh AC, Yee K, Sibai H, Minden MD, Wei C, Stockley T, Kamel-Reid S, Schimmer AD. Puckrin R, et al. Among authors: mcnamara c. Haematologica. 2021 Jan 1;106(1):56-63. doi: 10.3324/haematol.2019.235721. Haematologica. 2021. PMID: 31896684 Free PMC article.
549 results